• What is the Best Radionuclide for Immuno-PET of Multiple Myeloma? A Comparison Study Between 89Zr- and 64Cu-Labeled Anti-CD138 in a Preclinical Syngeneic Model, Bailly C, Gouard S, Guérard F, Chalopin B, Carlier T, Faivre-Chauvet A, et al., IJMS. 24 mai 2019;20(10):2564.

  • Preliminary results of a 68 Ga‐PSMA PET/CT prospective study in prostate cancer patients with occult recurrence: Diagnostic performance and impact on therapeutic decision‐making, Rousseau C, Le Thiec M, Ferrer L, Rusu D, Rauscher A, Maucherat B, et al. , Prostate. 17 août 2019;pros.23869

  • Potential for Nuclear Medicine Therapy for Glioblastoma Treatment, Bailly C, Vidal A, Bonnemaire C, Kraeber-Bodéré F, Chérel M, Pallardy A, et al., Front Pharmacol. 10 juill 2019;10:772.

  • FDG PET in Multiple Myeloma, Jamet B., Bailly C, Carlier T., Michaud A.V., Touzeau C., Moreau P., Bodet-Milin C., Kraeber-Bodere F., In: Molecular imaging in multiple myeloma. Springer.

  • Exploring Tumor Heterogeneity Using PET Imaging: The Big Picture, Bailly C, Bodet-Milin C, Bourgeois M, Gouard S, Ansquer C, Barbaud M, et al., Cancers. 31 août 2019;11(9):1282.

  • Clinical Results in Medullary Thyroid Carcinoma Suggest High Potential of Pretargeted Immuno-PET for Tumor Imaging and Theranostic Approaches, Bodet-Milin C, Bailly C, Touchefeu Y, Frampas E, Bourgeois M, Rauscher A, et al., Front Med. 4 juin 2019;6:124.

  • PET imaging of multiple myeloma: Comparison of 89Zr- and 64Cu-labeled anti-CD138 conjugates to 64CuCl2 and 18F-FDG in a preclinical syngeneic model. Bailly C, Gouard S, Chalopin B, Carlier T, Maurel C, Remaud-Le Saëc P, Bourgeois M, Chouin N, Tripier R, Haddad F, Faivre-Chauvet A, Kraeber-Bodéré F, Bodet-Milin C, Chérel M, 7th international workshop on PET in lymphoma and myeloma PIM, Menton, France, October 5-6 2018

    Preliminary results of prognostic added value of PET textural features at diagnosis in multiple myeloma with a long-term follow-up, Carlier T, Jamet B, Bailly C, Touzeau C, Moreau P, Bodet-Milin C, Kraeber-Bodéré F, 7th international workshop on PET in lymphoma and myeloma PIM, Menton, France, October 5-6 2018

    A population pharmacokinetics approach to evaluate the impact of the antibody dose in a context of lymphoma radioimmunotherapy (RIT) on dogs, Morio-Etienne F, Rajaud M, Becavin S, Piccirillo E, Touzot-Jourde G, Vidal A, Bourgeois M, Nguyen F, Abadie J, Varmenot N, Ferrer L, Bodet-Milin C, Ibisch C, Barbet J, Davodeau F, Chouin N, EANM’18 31th Annual congress of the European Association of Nuclear Medicine, Dusseldorf, Germany, oct 13-17 2018

  • Sensitivity of pretargeted immunoPET using 68Ga-peptide to detect colonic carcinoma liver metastases in a murine xenograft model: Comparison with 18FDG PET-CT, Foubert F, Gouard S, Saï-Maurel C, Chérel M, Faivre-Chauvet A, Goldenberg DM, Barbet J, Bodet-Milin C, Bailly C, Carlier T, Kraeber-Bodéré F, Touchefeu Y, Frampas E. Oncotarget 2018, 9:27502-27513

  • Synthesis of C-functionalized TE1PA and comparison with its analogues. An example of bioconjugation on 9E7.4 mAb for multiple myeloma 64Cu-PET imaging, Le Bihan T, Navarro AS, Le Bris N, Le Saëc P, Gouard S, Haddad F, Gestin JF, Chérel M, Faivre-Chauvet A, Tripier R, Org Biomol Chem. 2018, 16:4261-4271

  • Comparison of Immuno-PET of CD138 and PET imaging with 64CuCl2 and 18F-FDG in a preclinical syngeneic model of multiple myeloma. Bailly C, Gouard S, Lacombe M, Remaud-Le Saëc P, Chalopin B, Bourgeois M, Chouin N, Tripier R, Halime Z, Haddad F, Faivre-Chauvet A, Kraeber-Bodéré F, Chérel M, Bodet-Milin C, Oncotarget 2018, 9:9061-9072